Migraine drugs
According to recent studies, migraine affects more than 1 billion people worldwide, making it one of the world’s most prevalent diseases. Although this highly debilitating illness has been known since ancient times, the first therapeutic drugs to treat migraine, ergotamine (Gynergen) and dihydroergotamine (Dihydergot), did not appear on the market until 1921 and 1946, respectively. Both drugs originated from Sandoz, the world’s leading pharmaceutical company in ergot alkaloid research at the time. Historically, ergot alkaloids had been primarily used in obstetrics, but with methysergide (1-methyl-lysergic acid 1′-hydroxy-butyl-(2S)-amide), it became apparent that they also held some potential in migraine treatment. Methysergide was the first effective prophylactic drug developed specifically to prevent migraine attacks in 1959. On the basis of significantly improved knowledge of migraine pathophysiology and the discovery of serotonin and its receptors, Glaxo was able to launch sumatriptan in 1992. It was the first member from the class of triptans, which are selective 5-$ HT_{1B/1D} $ receptor agonists. Recent innovations in acute and preventive migraine therapy include lasmiditan, a selective 5-$ HT_{1F} $ receptor agonist from Eli Lilly, the gepants, which are calcitonin gene-related peptide (CGRP) receptor antagonists discovered at Merck & Co and BMS, and anti-CGRP/receptor monoclonal antibodies from Amgen, Pfizer, Eli Lilly, and others. Graphical abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
ChemTexts - 9(2023), 2 vom: 03. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramachanderan, Raghavendra [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Biosynthesis |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s40828-023-00178-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR049938754 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049938754 | ||
| 003 | DE-627 | ||
| 005 | 20230429064826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230405s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40828-023-00178-5 |2 doi | |
| 035 | |a (DE-627)SPR049938754 | ||
| 035 | |a (SPR)s40828-023-00178-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramachanderan, Raghavendra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Migraine drugs |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a According to recent studies, migraine affects more than 1 billion people worldwide, making it one of the world’s most prevalent diseases. Although this highly debilitating illness has been known since ancient times, the first therapeutic drugs to treat migraine, ergotamine (Gynergen) and dihydroergotamine (Dihydergot), did not appear on the market until 1921 and 1946, respectively. Both drugs originated from Sandoz, the world’s leading pharmaceutical company in ergot alkaloid research at the time. Historically, ergot alkaloids had been primarily used in obstetrics, but with methysergide (1-methyl-lysergic acid 1′-hydroxy-butyl-(2S)-amide), it became apparent that they also held some potential in migraine treatment. Methysergide was the first effective prophylactic drug developed specifically to prevent migraine attacks in 1959. On the basis of significantly improved knowledge of migraine pathophysiology and the discovery of serotonin and its receptors, Glaxo was able to launch sumatriptan in 1992. It was the first member from the class of triptans, which are selective 5-$ HT_{1B/1D} $ receptor agonists. Recent innovations in acute and preventive migraine therapy include lasmiditan, a selective 5-$ HT_{1F} $ receptor agonist from Eli Lilly, the gepants, which are calcitonin gene-related peptide (CGRP) receptor antagonists discovered at Merck & Co and BMS, and anti-CGRP/receptor monoclonal antibodies from Amgen, Pfizer, Eli Lilly, and others. Graphical abstract | ||
| 650 | 4 | |a Migraine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ergotamine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Triptans |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ditans |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Gepants |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Fischer indole synthesis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Total synthesis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Biosynthesis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Schramm, Stefan |0 (orcid)0000-0002-6109-0893 |4 aut | |
| 700 | 1 | |a Schaefer, Bernd |0 (orcid)0000-0002-1735-9795 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ChemTexts |d Berlin : Springer, 2015 |g 9(2023), 2 vom: 03. Apr. |w (DE-627)SPR03788834X |w (DE-600)2805594-9 |x 2199-3793 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:2 |g day:03 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40828-023-00178-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 2 |b 03 |c 04 | ||